Multiomic predictors for regression of cirrhosis: Clinical implications and future directions.
作者信息
Li Binghua, Yu Decai
机构信息
Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
出版信息
ILIVER. 2024 Sep 7;3(4):100116. doi: 10.1016/j.iliver.2024.100116. eCollection 2024 Dec.
Abstract
摘要
相似文献
1
Multiomic predictors for regression of cirrhosis: Clinical implications and future directions.肝硬化消退的多组学预测指标：临床意义与未来方向。
ILIVER. 2024 Sep 7;3(4):100116. doi: 10.1016/j.iliver.2024.100116. eCollection 2024 Dec.
2
Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.整合多组学分析确定了中国人群非酒精性脂肪性肝病的不同分子亚型。
Sci Transl Med. 2024 Nov 6;16(772):eadh9940. doi: 10.1126/scitranslmed.adh9940.
3
Diagnostic screening of COVID-19 based on multiomics data by high-resolution mass spectrometry (MALDI (+)-TOF MS and ESI(±)-Orbitrap MS).基于高分辨率质谱（基质辅助激光解吸电离飞行时间质谱（MALDI(+)-TOF MS）和电喷雾电离（±）-轨道阱质谱（ESI(±)-Orbitrap MS））的多组学数据对2019冠状病毒病进行诊断筛查。
Metabolomics. 2025 Jun 29;21(4):94. doi: 10.1007/s11306-025-02299-z.
4
Differentially abundant proteins, metabolites, and lipid molecules in spaghetti meat compared to normal chicken breast meat: Multiomics analysis.与正常鸡胸肉相比，意大利肉酱面肉馅中差异丰富的蛋白质、代谢物和脂质分子：多组学分析。
Poult Sci. 2025 Jul;104(7):105165. doi: 10.1016/j.psj.2025.105165. Epub 2025 Apr 14.
5
Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.粒细胞集落刺激因子联合或不联合干细胞或祖细胞或生长因子输注治疗代偿期或失代偿期晚期慢性肝病患者。
Cochrane Database Syst Rev. 2023 Jun 6;6(6):CD013532. doi: 10.1002/14651858.CD013532.pub2.
6
Multiomics reveals metformin's dual role in gut microbiome remodeling and hepatic metabolic reprogramming for MAFLD intervention.多组学揭示二甲双胍在肠道微生物群重塑和肝脏代谢重编程以干预非酒精性脂肪性肝病中的双重作用。
Sci Rep. 2025 Jul 2;15(1):22699. doi: 10.1038/s41598-025-07557-7.
7
Prediction of Weight Loss and Regain Based on Multiomic and Phenotypic Features: Results From a Calorie-Restricted Feeding Trial.基于多组学和表型特征预测体重减轻及体重反弹：热量限制喂养试验的结果
Diabetes Care. 2025 Jun 30. doi: 10.2337/dc25-0728.
8
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosis.与其他肝硬化病因相比，严重的α-1抗胰蛋白酶缺乏症在首次失代偿后出现并发症的风险更高。
JHEP Rep. 2025 Mar 20;7(6):101398. doi: 10.1016/j.jhepr.2025.101398. eCollection 2025 Jun.
9
Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions.非酒精性脂肪性肝病的治疗：现有选择和未来方向。
Clin Ther. 2021 Mar;43(3):500-517. doi: 10.1016/j.clinthera.2021.01.021. Epub 2021 Feb 12.
10
Multiomics approach provides insight into altered choline metabolism and liver injury in patients with glycogen storage disease type Ia.多组学方法有助于深入了解Ia型糖原贮积病患者胆碱代谢改变和肝损伤情况。
Sci Rep. 2025 Jul 1;15(1):20658. doi: 10.1038/s41598-025-06272-7.
本文引用的文献
1
Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression.对晚期慢性肝病患者进行代谢表型分析，以更好地描述肝硬化逆转。
J Hepatol. 2024 Dec;81(6):983-994. doi: 10.1016/j.jhep.2024.06.028. Epub 2024 Jun 27.
2
Regression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events.乙肝治疗患者的肝纤维化消退与肝脏相关事件减少相关。
Clin Gastroenterol Hepatol. 2024 Mar;22(3):591-601.e3. doi: 10.1016/j.cgh.2023.11.017. Epub 2023 Nov 30.
3
Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.多组学基于脂肪酸降解鉴定代谢亚型，为肝细胞癌分配个体化治疗。
Hepatology. 2024 Feb 1;79(2):289-306. doi: 10.1097/HEP.0000000000000553. Epub 2023 Aug 7.
4
A review of liver fibrosis and cirrhosis regression.肝纤维化与肝硬化逆转综述
J Pathol Transl Med. 2023 Jul;57(4):189-195. doi: 10.4132/jptm.2023.05.24. Epub 2023 Jun 20.
5
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies.器官纤维化的机制：新观点与新型治疗策略的启示。
Mol Aspects Med. 2023 Aug;92:101191. doi: 10.1016/j.mam.2023.101191. Epub 2023 May 24.
6
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression.肝脏纤维化消退的细胞和分子机制。
Cells. 2021 Oct 15;10(10):2759. doi: 10.3390/cells10102759.
7
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.肝硬化逆转与非酒精性脂肪性肝炎患者临床结局改善相关。
Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7.
8
Molecular and cellular mechanisms of liver fibrosis and its regression.肝纤维化及其逆转的分子和细胞机制。
Nat Rev Gastroenterol Hepatol. 2021 Mar;18(3):151-166. doi: 10.1038/s41575-020-00372-7. Epub 2020 Oct 30.
9
Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study.慢性乙型肝炎患者肝硬度下降不能提示纤维化逆转：一项 78 周前瞻性研究。
J Gastroenterol Hepatol. 2019 Apr;34(4):755-763. doi: 10.1111/jgh.14498. Epub 2018 Nov 8.
10
Fibrosis in chronic liver diseases: diagnosis and management.慢性肝病中的纤维化：诊断与管理
J Hepatol. 2005;42 Suppl(1):S22-36. doi: 10.1016/j.jhep.2004.12.008. Epub 2004 Dec 24.
Zotero 插件